Tumor volume and single voxel in vivo ¹H MRS were used to assess the effects of the choline
kinase inhibitor JAS239 in the F98 rat glioblastoma (GBM) model. Five F344 rats
were inoculated with GBM cells and subsequently treated for 5 consecutive days with
4 mg/kg JAS239 or saline. A reduction in total choline (tCho) in tumors treated
with JAS239, along with tumor growth arrest was noted in comparison to saline
treated rats. JAS239 preferentially inhibited choline metabolism in tumors as
no changes were observed in tCho levels from the contralateral brain.